BACKGROUND: The interaction between immune checkpoint blockade (ICB) and radiation (RT) for brain metastases has not been well understood. Given that acute neurotoxicity from this combination is not well characterized, we reviewed patients receiving ICB and RT for brain metastases. METHODS: Patients treated with ICB and cranial RT from 2010 through 2017 were reviewed. ICB and RT must have been administered within 30 days of each other. Treatment parameters, performance status, symptoms prior to treatment, and toxicity were extracted from the electronic medical record. Survival was calculated from the end of RT to last follow-up or death. RESULTS: Seventy-eight patients were included. Median follow-up was 177 days (range, 12-1603). Median age was 64 years old (range, 29-98) and 47 (63%) were male. The main tumor types were melanoma (n = 47) and nonsmall-cell lung cancer (n = 19). Fifty-seven patients were treated with stereotactic radiosurgery (SRS) and 21 with whole-brain radiotherapy (WBRT). Most patients received single-agent ICB, though 4 patients received nivolumab and ipilimumab. Forty-one (53%) patients reported no neurologic toxicity. Grade 2 or greater neurologic toxicities were reported in 12 (21%) and 8 (38%) patients in the SRS and WBRT groups, respectively. WBRT was associated with a greater risk of any neurotoxicity, though there was no correlation between ICB agent and toxicity. Sequencing of ICB and RT (ie, <30 days vs <7) did not influence rates of toxicity. CONCLUSIONS: ICB during SRS or WBRT does not appear to worsen acute neurotoxicity compared to historical controls of RT alone.
BACKGROUND: The interaction between immune checkpoint blockade (ICB) and radiation (RT) for brain metastases has not been well understood. Given that acute neurotoxicity from this combination is not well characterized, we reviewed patients receiving ICB and RT for brain metastases. METHODS: Patients treated with ICB and cranial RT from 2010 through 2017 were reviewed. ICB and RT must have been administered within 30 days of each other. Treatment parameters, performance status, symptoms prior to treatment, and toxicity were extracted from the electronic medical record. Survival was calculated from the end of RT to last follow-up or death. RESULTS: Seventy-eight patients were included. Median follow-up was 177 days (range, 12-1603). Median age was 64 years old (range, 29-98) and 47 (63%) were male. The main tumor types were melanoma (n = 47) and nonsmall-cell lung cancer (n = 19). Fifty-seven patients were treated with stereotactic radiosurgery (SRS) and 21 with whole-brain radiotherapy (WBRT). Most patients received single-agent ICB, though 4 patients received nivolumab and ipilimumab. Forty-one (53%) patients reported no neurologic toxicity. Grade 2 or greater neurologic toxicities were reported in 12 (21%) and 8 (38%) patients in the SRS and WBRT groups, respectively. WBRT was associated with a greater risk of any neurotoxicity, though there was no correlation between ICB agent and toxicity. Sequencing of ICB and RT (ie, <30 days vs <7) did not influence rates of toxicity. CONCLUSIONS: ICB during SRS or WBRT does not appear to worsen acute neurotoxicity compared to historical controls of RT alone.
Authors: M Werner-Wasik; S Rudoler; P E Preston; W W Hauck; B M Downes; D Leeper; D Andrews; B W Corn; W J Curran Journal: Int J Radiat Oncol Biol Phys Date: 1999-01-15 Impact factor: 7.038
Authors: Ana P Kiess; Jedd D Wolchok; Christopher A Barker; Michael A Postow; Viviane Tabar; Jason T Huse; Timothy A Chan; Yoshiya Yamada; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-05 Impact factor: 7.038
Authors: Andrew B Sharabi; Phuoc T Tran; Michael Lim; Charles G Drake; Theodore L Deweese Journal: Oncology (Williston Park) Date: 2015-05 Impact factor: 2.990
Authors: Lia M Halasz; Jane C Weeks; Bridget A Neville; Nathan Taback; Rinaa S Punglia Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-09 Impact factor: 7.038
Authors: Christopher A Barker; Michael A Postow; Shaheer A Khan; Kathryn Beal; Preeti K Parhar; Yoshiya Yamada; Nancy Y Lee; Jedd D Wolchok Journal: Cancer Immunol Res Date: 2013-07-25 Impact factor: 11.151
Authors: Henrik Hauswald; Jan-Oliver Dittmar; Daniel Habermehl; Stefan Rieken; Florian Sterzing; Jürgen Debus; Stephanie E Combs Journal: Radiat Oncol Date: 2012-08-02 Impact factor: 3.481
Authors: Pierre-Yves Borius; Jean Régis; Alexandre Carpentier; Michel Kalamarides; Charles Ambroise Valery; Igor Latorzeff Journal: Cancer Metastasis Rev Date: 2021-01-04 Impact factor: 9.264
Authors: Mark P van Opijnen; Linda Dirven; Ida E M Coremans; Martin J B Taphoorn; Ellen H W Kapiteijn Journal: Int J Cancer Date: 2019-11-23 Impact factor: 7.396